Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. Jazz Pharmaceuticals PLC's Company Profile. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families . References: American Cancer Society. Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Investor Relations Jazz Pharmaceuticals PLC . JAZZ earnings call for the period ending September 30, 2021. Jazz Pharmaceuticals and . JAZZ Jazz Pharmaceuticals PLC Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products . . Jazz Pharmaceuticals plc . Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. Media: Jacqueline Kirby Vice President, . Our decades of proven success come from passionate team members around the globe collaborating to bring the . About Jazz Pharmaceuticals plc . Investor Relations Jazz Pharmaceuticals PLC JAZZ Morningstar Rating Rating as of Mar 4, 2022. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Quote Stock Analysis News Price vs Fair Value . SUPN Stock Price Today by TradingView. Events and Presentations . 1 Hijiya N, van der Sluis IM. Jazz Pharmaceuticals PLC - Stock Analysis. It's been a good week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders, because the company has just released its latest yearly results, and the shares gained 7.4% to US$171. The specialty pharmaceutical company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.13. ET / 8:40 p.m. IST in Las Vegas. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Image source: The Motley Fool. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. Asparaginase-associated toxicity in children . Thank you, and good afternoon, everyone. ET / 7:00 p.m. IST in New York.. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . ET / 7:15 - 7:55 p.m. GMT.. A live audio webcast of the presentation may be accessed from the Investors section . . Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 . DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc . Innovating to Transform the Lives of Those with Sleep Disorders. . Investor Relations. Media: Jacqueline Kirby DUBLIN, June 7, 2022-- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) . References. Vice President, Head, Investor Relations. InvestorInfo@jazzpharma.com. Ireland +353 1 634 3211. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute . Supernus Pharmaceuticals, Inc. 9715 Key West Avenue. The Investor Relations website contains information about Jazz Pharmaceuticals plc's business for stockholders, potential investors, and financial analysts. Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Media: Kristin Bhavnani Head of Global Corporate Communications DUBLIN, July 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 second quarter financia. Thank . Print. Welcome to the Jazz Pharmaceuticals plc second-quarter 2019 earnings conference call. Jazz Pharmaceuticals plc JAZZ is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Contents: Prepared Remarks; . Jazz Pharmaceuticals PLC ( JAZZ 1.34%) Q1 2021 Earnings Call May 4, 2021, 4:30 p.m. 1-866-398-0833. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. You may begin. Home; . Press Releases . Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ETCompany Participants. ET. [Operator instructions] As a reminder, this conference call is being recorded. PR Newswire. Skip to main navigation Top Bar Nav Contact Us. Vice President, Head, Investor Relations. JAZZ. Cantor Virtual Global Healthcare Conference on Monday . Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2019 Results Earnings Conference Call November 5, 2019 4:30 PM ETCompany Participants. Jazz Investor Contact: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 . At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families. The transaction is expected to close in the third quarter of 2018 and is subject . Jazz Pharmaceuticals PLC ( JAZZ -2.04%) Q3 2021 Earnings Call. Jazz Pharmaceuticals plc [email protected] Ireland +353 1 637 2141 U.S. +1 215 867 4948. Jazz Pharmaceuticals plc (NASDAQ:NASDAQ:JAZZ) Q4 2020 Earnings Conference Call February 23, 2021 04:30 PM ET Company Participants Andrea Flynn - Head of Investor Relations Bruce Cozadd -. and Investor Relations 781.674.5284 ir@concertpharma.com. Investors News Releases Investors: Andrea N. Flynn, Ph.D.Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211. Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Business Description. Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email . Today, Jazz . Corporate The presentation will be available to registered conference attendees. Vice President, Head, Investor Relations. Investor Relations. . Media: Kristin Bhavnani Head of Global Corporate . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211. Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Katherine Littrell - Vice President, Investor Relations. . DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland, +353 1 634 3211. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy . The Investor Relations website contains information about Jazz Pharmaceuticals plc's business for stockholders, potential investors, and financial analysts. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement . Our current lead drug candidate, FT218, is . Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. InvestorInfo@jazzpharma.com. . Investor Relations. Learn about Jazz Pharmaceuticals PLC (JAZZ:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock . Printed . We'd be surprised if Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders haven't noticed that an insider, Elmar Schnee, recently sold US$251k worth of stock at US$154 per . Learn about Jazz Pharmaceuticals PLC (JAZZ:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock . Media: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc . In the coming days, we are showcasing our ongoing commitment to the sleep community with our presence at SLEEP 2022, the 36 th annual meeting of the Associated Professional Sleep Societies. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Andrea Flynn - Investor Relations. Morningstar Rating. ET / 7:00 p.m. IST in New York.. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . ET / 7:00 p.m. IST in New York.. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . Contents: Prepared Remarks; . Corporate - Footer Links 1. head of investor relations . Rating as of May 6, 2022. Welcome to the Jazz Pharmaceuticals plc first-quarter 2019 earnings conference call. . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211 U.S. +1 650 496 2717. References. About Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the . By transforming biopharmaceutical discoveries into . BofA Virtual Global Healthcare Conference 2021 on Wednesday, September 15, 2021 . Key statistics for lung cancer. DUBLIN, Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced Bruce Cozadd, chairman and chief executive officer, will present virtually as part of the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, from 2:15 - 2:55 p.m. Quote Stock Analysis News Price vs Fair Value Sustainability Trailing Returns Financials . Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious . Ireland +353 1 634 3211. . Rockville, MD 20850 (301) 838-2500. info@supernus.com. . DUBLIN, May 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2022 Global Healthcare Conference on Tuesday, May 10, 2022, at 12:40 p.m. PT / 3:40 p.m. | May 24, 2022 I will now turn the call over to Andrea Flynn, Head Investor Relations at Jazz Pharmaceuticals. Investor Relations Jazz . Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Jazz Pharmaceuticals plc. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Jazz Pharmaceuticals plc. InvestorInfo@jazzpharma.com. Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Q3 2021 Earnings Call Nov 9, 2021, 4:30 p.m. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on . ET. At Jazz, our purpose is to innovate to transform the lives of patients and their families. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. VP & Head of Investor Relations: N/A: N/A: N/A: Ms. Neena M. Patil J.D. Provided by PR Newswire May 4, 2022 1:10 PM PDT. Jun 01, 2022, 4:15 PM ET. investorinfo@jazzpharma.com Ireland: +353 1 634 7892 U.S.: +1 650 496 2800. Media: Kristin Bhavnani Head of Global Corporate . We are focused on developing life-changing medicines for people with serious diseases often with limited or no options so they can live their lives more fully. Social Icons . Investor Relations. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement . We are dedicated to developing life-changing . DUBLIN, April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: . [Operator instructions] I will now turn the call over to Kathee Littrell, head of investor relations at Jazz . Investor and Media Overview. Revenues came . These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)-- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced results from the recently completed Phase 1 clinical study of JZP-386, a deuterium-containing analog of sodium oxybate. Jazz Pharmaceuticals PLC (JAZZ) CEO Bruce Cozadd on Q3 2021 Results - Earnings Call Transcript. Media: Kristin Bhavnani Head of Global Corporate . Media Contact: Kristin Bhavnani Head of . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland, +353 1 634 3211 U.S., +1 650 496 2717. Nov 9, 2021, 4:30 p.m. ET. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Asparaginase-associated toxicity in children with . DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. . DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, . We are dedicated to developing life-changing medicines for people with serious diseasesoften with limited or no therapeutic options. Consensus estimates suggest investors . Head of Investor Relations at Jazz Pharmaceuticals. . Media: Kristin Bhavnani Head of Global Corporate Communications DUBLIN, June 29, 2018 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a definitive agreement to sell its rights related to Prialt (ziconotide) intrathecal infusion to TerSera Therapeutics LLC (TerSera) for $80 million in cash at closing. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Wednesday, May, 4th. Bruce . DUBLIN, Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences: . Jazz Investor Contact: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 . SA Transcripts Tue, Nov. 09, 2021. Review quarterly and annual revenue, net income, and cash flow for Jazz Pharmaceuticals PLC (JAZZ:XMEX) stock through the last fiscal year. Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz Pharmaceuticals plc. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211. Bruce Cozadd - Chairman and Chief . Investor and Media Overview. Supernus Support. Investor Home. This page shows recent SEC filings related to Jazz Pharmaceuticals PLC. DUBLIN, Oct. 26, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that it will report its 2021 third quarter financial results on Tuesday, November 9, 2021 after the close of the. ET. About Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the . Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Ireland +353 1 634 . Jazz Pharmaceuticals PLC (JAZZ 0.48%) Q4 2020 Earnings Call Feb 23, 2021, 4:30 p.m. We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Ms. Andrea N. Flynn Ph.D., VP & Head of Investor Relations; Ms. Neena M. Patil J.D., Chief Legal . Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Aug 13, 2021 7:07AM EDT. Jazz Pharmaceuticals PLC - Stock Analysis JAZZ. Jazz Pharmaceuticals Contacts: Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations. Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. 1 Hijiya N, van der Sluis IM. Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 .